The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

RNA FINANCIAL STATEMENTS

Atrium Therapeutics, Inc. Common Stock — balance sheet, income statement and cash flow trends

RNAAtrium Therapeutics, Inc. Common Stock

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-400 M-200 M0202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue36 M $Gross Profit35.5 M $ · 99%Operating Income-276.7 M $ · -769%Pre-tax Income-259.3 M $ · -721%Net Income to Owners-259.3 M $ · -721%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue36 M $+235.3%
Gross Profit35.5 M $—
Operating Income-276.7 M $—
EBITDA-260.1 M $—
Net Income to Owners-259.3 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0500 M1 B1.5 B202120222023202420252026

Capital Structure

Q2 2026
Total Assets280.5 M
  • Equity214.6 M $76%
  • Current Liabilities31.5 M $11%
  • Long-term Liabilities34.4 M $12%

Key Figures

YoY change
Total Assets280.5 M $-79.5%
Total Liabilities65.9 M $-62.6%
Total Equity214.6 M $-82.0%
Cash & ST Investments264.2 M $-77.7%
Total Debt1.7 M $-67.2%
Net Debt-71 M $—

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-600 M-400 M-200 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-1 B-500 M0-210.5 M $Operating-782.5 M $Investing1.2 B $Financing179 M $Net Change

Key Figures

YoY change
Operating Cash Flow-210.5 M $—
Capital Expenditures6.9 M $-45.7%
Free Cash Flow-217.4 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on RNA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 11, 26. This content is for informational purposes only and is not investment advice.